microtubule associated protein tau
microtubule associated protein tau
Overview
Microtubule associated protein tau is a neuronal protein encoded by MAPT that helps stabilize microtubules and supports axonal transport and neuronal maintenance. In the healthy nervous system, tau contributes to cytoskeletal organization and the structural integrity required for normal neuronal function. Its biological importance is underscored by the fact that disruption of tau regulation is strongly associated with tauopathies, a group of neurodegenerative disorders in which tau becomes abnormally modified and accumulates in pathological forms.
In disease contexts, tau is most prominently studied in Alzheimer's disease, where it is a major component of neurofibrillary tangles composed of hyperphosphorylated tau protein. Recent research contexts also emphasize that tau dysfunction can arise from an imbalance between kinases and phosphatases, altered MAPT exon 10 splicing, and the generation of truncated or modified tau species. These changes are linked to neuroinflammation, oxidative stress, neuronal loss, and impaired cognitive function, making tau a central therapeutic target in neurodegeneration.
Focus of Latest Publications
Recent publications consistently frame tau as a key target in Alzheimer’s disease and related neurodegenerative mechanisms. One study on therapeutic nanocarriers for 4-allyl pyrocatechol described Alzheimer’s disease as involving beta-amyloid accumulation, tau protein hyperphosphorylation, cholinergic dysfunction, oxidative stress, neuroinflammation, and neuronal loss, highlighting tau as part of the pathological cascade underlying cognitive decline. Another study developed a fractional-order model of Alzheimer’s disease using an Atangana-Baleanu-Caputo operator to capture the spatiotemporal spread of amyloid-beta and tau protein, indicating that tau propagation was treated as a dynamic biomarker process in disease progression.
Tau was also central in a machine learning-driven screening study of multitarget kinase inhibitors for tauopathy-associated neurodegeneration. That work explicitly noted that tauopathies arise when normal tau functions in axonal transport and neuronal maintenance are disrupted by an imbalance between kinases and phosphatases. In the same context, dual-specificity Tyrosine-Regulated Kinase 1A was highlighted as a regulator of MAPT exon 10 splicing and as a kinase that phosphorylates tau at multiple Ser/Thr residues, priming it for further phosphorylation by other kinases. This supports the view that tau pathology is not only a consequence of aggregation, but also of upstream regulatory and post-translational control.
Several studies treated tau as a therapeutic target rather than only a biomarker. A chemical space analysis used a dataset of 5,211 compounds that inhibit tau protein, explicitly identifying tau as a key therapeutic target for Alzheimer’s disease. Another Alzheimer’s-focused study noted that current therapeutic approaches targeting amyloid-β or tau pathology have largely failed to rescue synaptic function, reinforcing the clinical challenge of translating tau-directed strategies into effective disease modification. A separate review of CRISPR-Cas9 and next-generation gene editing strategies listed MAPT among critical genes considered for therapeutic intervention in Alzheimer’s disease, placing tau within broader gene-editing approaches aimed at neurodegenerative pathways.
New tau species were also reported. A translational neurodegeneration study identified and characterized a novel N-terminally truncated and N-alpha-acetylated tau form, named AcMet11-Tau, described as a pathological truncated tau species with functional relevance in Alzheimer’s disease. This adds to the growing recognition that tau pathology involves multiple molecular forms, not just full-length hyperphosphorylated protein.
Outside classical Alzheimer’s research, tau appeared in a cancer-related context where a metagene-based classification study in non-small cell lung cancer noted that a signaling process “in turn modulates Tau protein activity.” While the publication context does not establish a direct therapeutic role for tau in that setting, it indicates that tau-related biology may intersect with broader signaling networks beyond neurodegeneration.